Luminex (LMNX) Earns Market Perform Rating from William Blair

Share on StockTwits

Luminex (NASDAQ:LMNX)‘s stock had its “market perform” rating reissued by research analysts at William Blair in a report released on Tuesday, Zacks.com reports. William Blair also issued estimates for Luminex’s Q3 2019 earnings at $0.07 EPS, Q4 2019 earnings at $0.10 EPS and FY2019 earnings at $0.17 EPS.

Other analysts have also recently issued reports about the company. BidaskClub upgraded Luminex from a “sell” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research cut Luminex from a “hold” rating to a “sell” rating in a research report on Monday, April 8th. Finally, ValuEngine cut Luminex from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $31.33.

Shares of LMNX stock opened at $21.98 on Tuesday. The company has a market cap of $1.07 billion, a P/E ratio of 45.79, a P/E/G ratio of 6.17 and a beta of 0.75. Luminex has a twelve month low of $20.40 and a twelve month high of $35.37.

Luminex (NASDAQ:LMNX) last announced its quarterly earnings results on Monday, May 6th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.14). The company had revenue of $82.41 million for the quarter, compared to analysts’ expectations of $83.10 million. Luminex had a net margin of 5.81% and a return on equity of 4.61%. The firm’s revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.30 earnings per share. As a group, equities analysts predict that Luminex will post 0.26 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. Mason Street Advisors LLC increased its position in shares of Luminex by 3.6% during the first quarter. Mason Street Advisors LLC now owns 13,343 shares of the medical instruments supplier’s stock worth $307,000 after purchasing an additional 468 shares in the last quarter. Meeder Asset Management Inc. increased its position in shares of Luminex by 11.1% during the first quarter. Meeder Asset Management Inc. now owns 4,925 shares of the medical instruments supplier’s stock worth $113,000 after purchasing an additional 491 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Luminex by 2.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 29,688 shares of the medical instruments supplier’s stock worth $686,000 after purchasing an additional 652 shares in the last quarter. Piedmont Investment Advisors Inc. increased its position in shares of Luminex by 7.0% during the first quarter. Piedmont Investment Advisors Inc. now owns 10,695 shares of the medical instruments supplier’s stock worth $246,000 after purchasing an additional 695 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Luminex by 0.6% during the first quarter. Rhumbline Advisers now owns 128,066 shares of the medical instruments supplier’s stock worth $2,947,000 after purchasing an additional 822 shares in the last quarter. Institutional investors and hedge funds own 85.52% of the company’s stock.

Luminex Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

Featured Article: What is a capital gain?

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.